2830 Diabetes Care Volume 37, October 2014 Felix O. Dupont,1 Marie-France Hivert,1,2,3 Glycation of Fetal Hemoglobin Catherine Allard,1 Julie Menard,´ 1 Patrice Perron,1,2 Luigi Bouchard,1,4,5 Reflects Hyperglycemia Exposure Julie Robitaille,6 Jean-Charles Pasquier,1,7 Christiane Auray-Blais,1,8 and In Utero Jean-Luc Ardilouze1,2 Diabetes Care 2014;37:2830–2833 | DOI: 10.2337/dc14-0549 OBJECTIVE The lifetime risk of metabolic diseases in offspring of women with gestational diabetes mellitus (GDM) depends, at least in part, on the impact of glycemic fetal programming. To quantify this impact, we have developed and validated a unique mass spectrometry method to measure the percentage of glycated hemoglobin in cord blood. RESEARCH DESIGN AND METHODS This case-control study includes 37 GDM women and 30 pregnant women with normal glucose tolerance (NGT). RESULTS Glycation of the a-chain (Gla) was higher in neonates from GDM (2.32 vs. 2.20%, P < 0.01). Gla strongly correlated with maternal A1C measured at delivery in the r P < r P < overall cohort ( =0.67, 0.0001) as well as in each group (GDM: = 0.66, 1 r P Centre de Recherche du Centre Hospitalier Uni- 0.0001; NGT: = 0.50, = 0.01). versitaire de Sherbrooke, Sherbrooke, QC, Canada 2Endocrine Division, Universite´ de Sherbrooke, CONCLUSIONS Sherbrooke, QC, Canada Thus, Gla may reflect hyperglycemic exposure during the last weeks of fetal de- 3Harvard Pilgrim Health Care Institute, Depart- velopment. Future studies will confirm Gla is a predictive biomarker of prenatally ment of Population Medicine, Harvard Medical School, Boston, MA programmed lifetime metabolic health and disease. 4Department of Biochemistry, Universitede´ Sherbrooke, Sherbrooke, QC, Canada The fetal programming theory suggests that maternal hyperglycemia during pregnancy 5ECOGENE-21 and Lipid Clinic, Chicoutimi Hospi- tal, Saguenay, QC, Canada has lifelong consequences for metabolic health in offspring (1,2). However, assessing 6 fl Department of Food Science and Nutrition, fetal impacts poses a challenge. Birth weight is often used as a marker but is in uenced Laval University, Quebec, QC, Canada by multiple determinants (3). Cord blood glucose, C-peptide, and insulin are also 7Department of Gynaecology-Obstetrics, Uni- measured, albeit only once upon delivery (4–6), despite labor-associated stress and versite´ de Sherbrooke, Sherbrooke, QC, Canada exercise affecting fetal glucose metabolism in opposite ways. A marker of long-term 8Department of Pediatrics, UniversitedeSher-´ fetal glucose metabolism is needed. Although fetal A1C was a promising candidate, its brooke, Sherbrooke, QC, Canada NOVEL COMMUNICATIONS IN DIABETES measurement consistently resisted standard methods because of technical difficulties Corresponding author: Jean-Luc Ardilouze, jean-luc. [email protected]. in face of wide biological variations (7). We have recently developed an accurate method to measure glycation of hemo- Received 2 March 2014 and accepted 26 June 2014. globin (Hb) chains in fetal cord blood (8). Here, we compare results from neonates Clinical trial reg. no. NCT01025973, clinicaltrials born to women with gestational diabetes mellitus (GDM) and women with normal .gov. glucose tolerance (NGT). F.O.D. and M.-F.H. contributed equally to this RESEARCH DESIGN AND METHODS study. © 2014 by the American Diabetes Association. Research Design Readers may use this article as long as the work This case-control study includes 37 women diagnosed and treated for GDM (all were is properly cited, the use is educational and not under insulin therapy) and 30 pregnant women classified as NGT. This case-control for profit, and the work is not altered. care.diabetesjournals.org Dupont and Associates 2831 study included all neonates previously in coefficients of variation (CVs) for Gla delivered earlier (38.5 6 0.8 vs. 39.8 6 our method development (8). Addi- levels were 2.10/3.72%. The linearity 0.9 weeks, P , 0.001). GDM neonates tional participants were included in (r2)ofthea-chain glycation response, were normoglycemic (4.1 6 0.9 vs. this project aiming at investigating the measured from 1.97 to 3.11%, was 4.3 6 0.8 mmol/L, P = NS) but displayed pathophysiology relevance of measur- 0.9990. In the current samples, the min- hyperinsulinemia (89 6 104 vs. 41 6 32 ing fetal A1C, but always with the imum value that we measured was 1.9% pmol/L, P = 0.02) and impaired insulin same inclusion and exclusion criteria as and the maximum value was 2.8%; the sensitivity as estimated by the glucose- when recruiting for method develop- interquartile range was 2.12–2.40%. to-insulin ratio (0.09 6 0.06 vs. 0.14 6 ment. According to Canadian recom- 0.06, P =0.01). mendations (9), GDM was defined in Biomarker Measurements The mean level of Gla was higher in Maternal A1C (Bio-Rad VARIANT, Hercu- this study as two out of three abnormal GDM neonates (2.32 vs. 2.20%, P =0.01) les, CA) analysis was performed by plasma glucose values during the 75-g and was correlated with maternal A1C the Centre Hospitalier Universitaire de oral glucose tolerance test (fasting $5.3, levels in the overall group (r =0.67,P , Sherbrooke (CHUS) Clinical Biochemis- 1h$10.6, and 2 h $8.9 mmol/L). 0.0001) and in each group (GDM: r = try laboratory. Cord blood samples for Exclusion criteria were as follows: 0.66, P , 0.0001; NGT: r =0.50,P = future measurements were centrifuged multiple pregnancies, mother’s first tri- 0.01). Gla was not correlated with birth at 2,500g during 10 min at 48C. Aliquots mester BMI $30 kg/m2, gestational age weight (GDM: r =0.16,P = 0.34; NGT: r = of plasma were stored at 2808C until ,37 weeks, and neonate birth weight 0.03, P = 0.88) or with gestational age measurement. Glucose was measured ,2,500 g. Gestational age was deter- (GDM: r =0.01,P =0.96;NGT:r =0.09, using a colorimetric method (Wako mined based on ultrasound dating, a P =0.64). Diagnostics, Mountain View, CA); the standardized clinical procedure at our intra-assay and interassay CVs were institution. CONCLUSIONS both ,5%; minimum detectable con- Maternal weight and height at first Gla was higher in neonates exposed to centration was 0.28 mmol/L. For insulin, trimester and data related to delivery GDM. Our sophisticated MS method al- C-peptide, and proinsulin concentration and neonatal outcomes were retrieved lows for precise Gla measurement, in- measurements (radioimmunoassay; from medical records. Blood for mater- dependently of the HbF-to-HbA ratio Millipore Corp., Billerica, MA), the nal A1C measurements was sampled (8). Standard methods for measuring fe- intra-assay and interassay CVs were upon arrival at the Obstetrics Depart- tal Hb glycation have consistently failed, all ,10% for the three analytes; mini- ment, before delivery. Cord blood sam- due to inherent inaccuracy (7,10) and mum detectable concentrations of insu- ples for glycation measurements were the wide range of HbF (65–90% in term lin, C-peptide, and proinsulin were, collectedwithin15minafterdelivery, neonates) and HbA variations attribut- respectively, 16.29 pmol/L, 0.033 ng/mL, in BD Vacutainer tubes with sodium able to individual characteristics and fe- and 3.055 pmol/L. fluoride/Na2-EDTA as an additive (8). tal gestational age (11). An alternative Insulin sensitivity was assessed by the Statistical Analyses method using electrospray ionization glucose-to-insulin ratio in cord blood (6). Continuous variables were assessed for MS has been proposed before but re- distribution and log transformed to mained with limitations (12); as demon- Principles achieve normal distribution as neces- strated in our methodology paper (8), Hb in cord blood is a composite of HbF sary. Variables were compared between we were able to clearly establish the (a2g2 chains) and HbA (a2b2). Accord- groups (GDM vs. NGT) using Student linearity of the response, selectivity, ing to our previous analyses (8), only t test or Mann-Whitney U test depending and data deconvolution processing in a glycation of the a-chain (Gla)wasspe- on the normality of the distribution. Fre- range that is appropriate for measure- cifically assessed in this study because of quencies, presented as percentages, ment of glycation of a-andg-chains. the following: 1)thea-chain is common were compared using x2 tests. Correla- Here, we reported associations with to HbF and HbA and represents the sum tions between maternal/neonatal char- clinically relevant maternal and fetal of both forms, which are produced by acteristics and the level of glycation of glycemic traits. the fetus; 2)thea-chain is not a function the a-chain were assessed by Pearson Because fetal Hb life span is 60–80 of the HbF-to-HbA ratio, an important coefficients. P values ,0.05 were con- days (11), we assumed that Gla reflects consideration since this ratio is not 1:1 sidered significant. Statistical analyses mean fetal glucose exposure over the and varies substantially at birth; and 3) were performed using SAS version 9 last 4–6 weeks of pregnancy. Most im- the number of g-chain variants and (SAS Institute, Cary, NC). portantly, the strong correlations with b-chain methodological interferences maternal A1C levels suggest that Gla ac- make the measurement of these chains RESULTS curately reflects the degree of hypergly- unsuitably long. GDM women (Table 1) were heavier at cemia exposure. One could argue that Glycation of Hb chains was measured first trimester (BMI = 27.6 6 5.7 vs. maternal A1C may also serve as marker using a quadrupole orthogonal acceler- 24.6 6 5.9 kg/m2, P = 0.04) and had a of glycemic exposure; yet given the im- ation time-of-flight mass spectrometer higher A1C at delivery time (5.8 6 0.4 perfect, albeit strong, correlation, we (SYNAPT MS; Waters Corporation, Mil- vs.